Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Follicle Stimulating Hormone Market:By Product Type, By Application, By End Users and Geography
The global Follicle Stimulating Hormone (FSH) Market size is expected to reach US$ 3.4 billion by 2028, at a CAGR of 4.6% during the forecast period 2023-2029. Follicle stimulating hormone (FSH) is a gonadotropic hormone secreted by anterior pituitary gland. It helps in the development of pubertal maturation, and reproductive process. FSH regulates the functions of testes and ovaries. Insufficiency of follicle stimulating hormone may cause the subfertility or infertility in women and men. However, stringent regulatory guidelines for product approval, alternative procedures for infertility, and lack of awareness in underdeveloped countries may restrain the growth of Follicle Stimulating Hormone (FSH) Market. FSH is a glycoprotein that promotes egg growth in female ovaries and sperm generation in male testes. FSH affects the ovarian follicles directly, prompting them to develop and produce oestrogen. It also causes the Mullerian ducts to regress, triggering gonadal growth, maturation, and steroidogenesis in both sexes by activating particular Leydig cells to generate testosterone or a Mullerian inhibitory chemical. It can also be used in conjunction with human chorionic gonadotropin to induce ultimate oocyte maturation in the clinic (hCG). In addition, a growing number of research utilising animal models such as mice have revealed that LH plays a role in boosting neurological function by enhancing synaptic plasticity and memory. The primary goals of an FSH test in women are to detect abnormalities in menstrual cycles in young females or to suspect the onset of menopause in middle-aged women. FSH tests, like clinical investigative investigations for women, can assist determine a man's sperm count. As the medical sector undergoes significant transition, it piques healthcare professionals' interest in clinical trials involving follicles and hormones in people. The commercial exposure of diagnostic treatments and procedures is induced by the use of standard specimens and funding for research projects. The impacts of climate change and the external environment on human health and follicles are also examined in a predicted study.
Study Period
2024-2030Base Year
2023CAGR
4.6%Largest Market
North AmericaFastest Growing Market
Europe
Growing incidence of infertility in both men and women due to change in lifestyle, rise in R&D for the synthesis of follicle stimulating hormone (FSH), growing awareness about the follicle stimulating hormones among physicians, and increase in healthcare expenditure are anticipated to fuel the growth of follicle stimulating hormone market over the forecast period.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2028 |
US$ 3.4 billion |
Market CAGR |
4.6% |
Product Type |
|
Application |
|
End User |
|
Download Free Sample Report
The global Follicle Stimulating Hormone (FSH) Market size is expected to reach US$ 3.4 billion by 2029
Merck Serono (Germany), Merck Sharp & Dohme Corp. (Merck & Co. Inc.) (U.S.), Ferring B.V. (Switzerland), IBSA Institut Biochimque SA (Switzerland)
North America is the fastest-growing region for the follicle-stimulating hormone (FSH) market
follicle stimulating hormone (FSH) market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The key opportunities for the follicle stimulating hormone (FSH) market include its use in fertility treatments, menopausal hormone therapy, and potential applications in diagnosing certain medical conditions, driving market growth.
1.Executive Summary |
2.Global Follicle Stimulating Hormone (FSH) Market Introduction |
2.1.Global Follicle Stimulating Hormone (FSH) Market - Taxonomy |
2.2.Global Follicle Stimulating Hormone (FSH) Market - Definitions |
2.2.1.Product Type |
2.2.2.Application |
2.2.3.End User |
2.2.4.Region |
3.Global Follicle Stimulating Hormone (FSH) Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Follicle Stimulating Hormone (FSH) Market Analysis, 2018-2022 and Forecast 2023-2029 |
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Follicle Stimulating Hormone (FSH) Market By Product Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
5.1. Recombinant Follicle Stimulating Hormone |
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Urinary Follicle Stimulating Hormone |
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6.Global Follicle Stimulating Hormone (FSH) Market By Application, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
6.1. Assisted Reproductive Technology |
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Infertility Treatment |
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7.Global Follicle Stimulating Hormone (FSH) Market By End User, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
7.1. Hospitals |
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Gynecology Clinics |
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Infertility Centers |
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Follicle Stimulating Hormone (FSH) Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Follicle Stimulating Hormone (FSH) Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
9.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Recombinant Follicle Stimulating Hormone |
9.1.2.Urinary Follicle Stimulating Hormone |
9.2. Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Assisted Reproductive Technology |
9.2.2.Infertility Treatment |
9.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospitals |
9.3.2.Gynecology Clinics |
9.3.3.Infertility Centers |
9.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Follicle Stimulating Hormone (FSH) Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
10.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Recombinant Follicle Stimulating Hormone |
10.1.2.Urinary Follicle Stimulating Hormone |
10.2. Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Assisted Reproductive Technology |
10.2.2.Infertility Treatment |
10.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospitals |
10.3.2.Gynecology Clinics |
10.3.3.Infertility Centers |
10.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
10.4.6.Rest of EU |
10.4.7. |
11.Asia Pacific (APAC) Follicle Stimulating Hormone (FSH) Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Recombinant Follicle Stimulating Hormone |
11.1.2.Urinary Follicle Stimulating Hormone |
11.2. Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Assisted Reproductive Technology |
11.2.2.Infertility Treatment |
11.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospitals |
11.3.2.Gynecology Clinics |
11.3.3.Infertility Centers |
11.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Follicle Stimulating Hormone (FSH) Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Recombinant Follicle Stimulating Hormone |
12.1.2.Urinary Follicle Stimulating Hormone |
12.2. Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Assisted Reproductive Technology |
12.2.2.Infertility Treatment |
12.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospitals |
12.3.2.Gynecology Clinics |
12.3.3.Infertility Centers |
12.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Follicle Stimulating Hormone (FSH) Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
13.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Recombinant Follicle Stimulating Hormone |
13.1.2.Urinary Follicle Stimulating Hormone |
13.2. Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Assisted Reproductive Technology |
13.2.2.Infertility Treatment |
13.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospitals |
13.3.2.Gynecology Clinics |
13.3.3.Infertility Centers |
13.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Merck Serono (Germany) |
14.2.2.Merck Sharp & Dohme Corp. (Merck & Co. Inc.) (U.S.) |
14.2.3.Ferring B.V. (Switzerland) |
14.2.4.IBSA Institut Biochimque SA (Switzerland) |
14.2.5.Livzon Pharmaceutica Group Inc. (Hong Kong) |
14.2.6.Techwell Inc. (U.S.) |
14.2.7.Gedeon Richter Plc (Hungary) |
14.2.8.GenScience Pharmaceuticals Co. Ltd. (Changchun High & New Tech) (China) |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players